USPTO Examiner COUGHLIN DANIEL F - Art Unit 1619

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19272053BIOLOGIC MATRIX FOR A WOUND SITE AND RELATED METHODSJuly 2025January 2026Allow600NoNo
19098518EXTRACELLULAR MATRIX HYDROGEL MICROSPHERE, AND PREPARATION METHOD AND APPLICATION THEREOFApril 2025August 2025Allow501NoNo
19037073ORGANIC DENTAL GUM AND METHOD OF FABRICATING THE DENTAL GUMJanuary 2025August 2025Allow601NoNo
18971812TREATED OSSEOUS PARTICULATE FLUFF COMPOSITIONDecember 2024August 2025Abandon810NoNo
18934892USE OF ENCAPSULATED CELL THERAPY FOR TREATMENT OF OPHTHALMIC DISORDERSNovember 2024July 2025Allow910NoNo
188969543D PRINTED BONE DEFECT REPAIR SCAFFOLD LOADED WITH EXTRACELLULAR MATRIX OF MESENCHYMAL STEM CELLS AND PREPARATION METHOD THEREOFSeptember 2024May 2025Abandon810NoNo
18841788DOUBLE-CROSSLINKED FIBRIN GEL, RAW MATERIAL COMPOSITION AND KIT THEREOF, AND APPLICATION THEREOFAugust 2024June 2025Allow910NoNo
18659750TRANSDERMAL CANNABIDIOL DELIVERY DEVICEMay 2024April 2025Allow1121YesNo
18624746BIOLOGIC MATRIX FOR A WOUND SITE AND RELATED METHODSApril 2024September 2024Allow510NoNo
18606551CONTACT LENSES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING STABILIZERS OF LABILE COMPONENTS SUCH AS DRUGSMarch 2024August 2024Allow501NoNo
18606678PEDIATRIC POWDER FOR ORAL SUSPENSION CONTAINING ANTIVIRAL AGENT AND METHOD FOR THE PREPARATION THEREOFMarch 2024September 2025Allow1821NoNo
18418010TREATMENT OF DEPRESSIONJanuary 2024July 2025Abandon1820NoNo
18542059BONE REGENERATION MATERIAL HAVING A COTTON-WOOL LIKE STRUCTURE FORMED OF A PLURALITY OF ELECTROSPUN FIBERSDecember 2023February 2025Abandon1411NoNo
18527884USE OF ENCAPSULATED CELL THERAPY FOR TREATMENT OF OPHTHALMIC DISORDERSDecember 2023March 2025Allow1510NoNo
18448259BIOLOGIC MATRIX FOR A WOUND SITE AND RELATED METHODSAugust 2023April 2024Allow811NoNo
18448250BIOLOGIC MATRIX FOR A WOUND SITE AND RELATED METHODSAugust 2023July 2025Allow2341NoNo
18349570EPHEDRINE LIQUID FORMULATIONSJuly 2023May 2025Abandon2211NoNo
18259697TRANSDERMAL PSYCHOACTIVE ALKALOID COMPOSITION AND PREPARATION THEREOFJune 2023April 2024Allow911NoNo
18312445SYSTEMS AND METHODS FOR BONE REPAIR AND MANAGEMENT USING BIOCOMPATIBLE POLYMERIC RESINMay 2023September 2024Abandon1611NoNo
18302975CONTROLLING NEUROPATHIC PAINApril 2023September 2024Allow1710NoNo
18249044EFFICIENT BIPHASIC CALCIUM PHOSPHATE COATING METHODApril 2023October 2025Allow3001NoNo
18189773Transdermal Delivery System Containing RotigotineMarch 2023July 2025Abandon2821NoNo
18110648The Use of a Hemocompatible Porous Polymer Bread Sorbent for Removal of Pamps and DampsFebruary 2023September 2025Abandon3121NoNo
18098518PHARMACEUTICAL OR NUTRACEUTICAL SELF-EMULSIFYING SOLID DISPERSION COMPOSITIONJanuary 2023January 2026Allow3640NoYes
18153590CONTROL METHOD OF LOCAL RELEASE FOR TARGET COMPOUNDS BY USING PATTERNING HYDROGEL TO NANOPOROUS MEMBRANEJanuary 2023January 2026Allow3611NoNo
18093931Oral Drug Delivery System and Method for Fabricating ThereofJanuary 2023March 2025Abandon2621NoNo
18070319Methods and compositions for treatment with donepezilNovember 2022October 2024Abandon2311NoNo
18070334Microcapillary Mesh Oxygen Transporter for Cell TransplantationsNovember 2022June 2025Allow4101NoNo
17999882ION-SUBSTITUTED BOVINE HYDROXYAPATITE FOR BONE REGENERATIONNovember 2022October 2025Allow3401NoNo
17990863Enriched Withania somnifera Based Dietary Composition and a Method ThereofNovember 2022September 2025Allow3401NoNo
17984291MEDICAL ADHESIVE AND PREPARATION METHOD THEREOFNovember 2022October 2024Allow2301NoNo
17981383FORMULATIONS OF PTHrP ANALOGUES, TRANSDERMAL PATCHES THEREOF, AND USES THEREOFNovember 2022August 2024Abandon2110NoNo
17969282Packaged Silicone Lubricated Condom That Provides SensationOctober 2022June 2024Abandon2011NoNo
17822168SCAFFOLD COMPRISING SURFACE HYPERBOLOID STRUCTURE, METHODS FOR FABRICATION AND USE THEREOFSeptember 2022October 2025Allow3731NoNo
17932621SLOW RELEASE PHARMACEUTICAL COMPOSITION MADE OF MICROPARTICLESSeptember 2022December 2024Abandon2720NoNo
17945575ELECTROSPINNING OF CARTILAGE AND MENISCUS MATRIX POLYMERSSeptember 2022March 2025Abandon3021NoNo
17902303MICRONEEDLE DEVICESeptember 2022February 2024Abandon1710NoNo
17900245RAPIDLY-ORODISPERSIBLE TABLETS HAVING AN INTERIOR CAVITYAugust 2022August 2025Allow3520NoYes
17819346Structural Implant to Prevent Bone DefectsAugust 2022March 2025Allow3121NoNo
17813517ABUSE RESISTANT CAPSULEJuly 2022July 2024Allow2411YesNo
17868066HYDRATABLE AND FLOWABLE IMPLANTABLE COMPOSITIONS AND METHODS OF MAKING AND USING THEMJuly 2022November 2025Allow4011NoNo
17863638PEDIATRIC POWDER FOR ORAL SUSPENSION CONTAINING ANTIVIRAL AGENT AND METHOD FOR THE PREPARATION THEREOFJuly 2022September 2025Allow3840NoNo
17848418METHODS OF TREATMENT USING NICLOSAMIDEJune 2022September 2024Abandon2621YesNo
17838810TRANSDERMAL DRUG DELIVERY SYSTEM FOR KETAMINEJune 2022January 2024Abandon1910NoNo
17834561DRY INFLATED DECELLULARIZED EXTRACELLULAR MATRIXJune 2022September 2024Allow2821NoNo
17829627PINOCEMBRIN DIHYDROCHALCONE AND COMPOSITIONS THEREOF AND THEIR USE AS PESTICIDESJune 2022April 2025Allow3401NoNo
17664792Biodegradable Porous Membrane for Generating Scaffold-Free Biological AssembliesMay 2022September 2025Allow4031NoNo
17735868COMBINATION GRAFTS FOR TISSUE REPAIR OR REGENERATION APPLICATIONSMay 2022November 2025Allow4331YesNo
17731348METHODS AND COMPOSITION FOR INDUCTION OF IMMUNE RESPONSEApril 2022December 2024Allow3200NoNo
17732456METHOD OF TREATMENT AND DEVICE FOR THE IMPROVED BIOAVAILABILITY OF LEUKOTRIENE RECEPTOR ANTAGONISTSApril 2022February 2026Allow4530NoYes
17729442METHOD OF TREATMENT AND DEVICE FOR THE IMPROVED BIOAVAILABILITY OF LEUKOTRIENE RECEPTOR ANTAGONISTSApril 2022November 2025Abandon4340NoNo
17722936Method of Controlling Insects and Insecticide for Use ThereinApril 2022November 2024Abandon3120NoNo
17768361DEODORANT COMPOSITION, ABSORBENT, AND ABSORBENT ARTICLEApril 2022July 2025Allow3910NoNo
17712755MICRONEEDLE PARTICLES, COMPOSITIONS, AND METHODS OF TREATMENT AND DELIVERING A SUBSTANCE OF INTERESTApril 2022April 2024Allow2411NoNo
17696752WATER-SOLUBLE FORMULATIONS, METHODS OF MAKING AND USEMarch 2022April 2023Abandon1311NoNo
17654963BOUNDARY SURFACE CHARGED CONTACT LENS FOR DELIVERYMarch 2022August 2022Allow501NoNo
17692460POROUS TRICALCIUM PHOSPHATE MATERIAL, METHOD FOR BONE HEALING USING THE SAME, AND MANUFACTURING METHOD THEREOFMarch 2022June 2024Allow2811NoNo
17588659MEDICAL DEVICES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING ENHANCING COMFORT, ENHANCING DRUG PENETRATION, AND TREATMENT OF MYOPIAJanuary 2022July 2022Allow500YesNo
17579810LIQUID ANTIMICROBIAL COMPOSITIONJanuary 2022December 2025Abandon4711NoNo
17625446HAIR CARE COMPOSITION COMPRISING ANTIDANDRUFF AGENTJanuary 2022March 2026Abandon5021NoNo
17570216TRANSMUCOSAL DRUG DELIVERY DEVICES FOR USE IN CHRONIC PAIN RELIEFJanuary 2022December 2023Abandon2310NoNo
17596507AGRICULTURAL FILM AND USEDecember 2021October 2025Allow4720YesNo
17545931METHOD FOR PREPARING A BONE PROTEIN PREPARATION AND A BONE PROTEIN PREPARATIONDecember 2021May 2024Allow2911NoNo
17542432EPHEDRINE LIQUID FORMULATIONSDecember 2021August 2023Abandon2021NoNo
17613758METHOD AND COMPOSITION FOR WATER TREATMENTNovember 2021November 2025Allow4811NoNo
17529402USE OF ENCAPSULATED CELL THERAPY FOR TREATMENT OF OPHTHALMIC DISORDERSNovember 2021January 2024Abandon2510NoNo
17454846METHOD FOR PREPARING CERAMIC MATERIALSNovember 2021January 2024Allow2601NoNo
17519336POROUS COMPOSITE BIOMATERIALS AND RELATED METHODSNovember 2021March 2024Allow2931YesYes
17513307RAPIDLY-ORODISPERSIBLE TABLETS HAVING AN INTERIOR CAVITYOctober 2021May 2022Allow601YesNo
17604567BRIVARACETAM PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOFOctober 2021September 2025Abandon4721NoNo
17603448TISSUE DERIVED POROUS MATRICES AND METHODS FOR MAKING AND USING SAMEOctober 2021April 2025Allow4231YesNo
17485766BIOACTIVE POROUS BONE GRAFT IMPLANTSSeptember 2021May 2024Allow3111NoNo
17437173PHOTOTHERMAL THERAPY PROMOTES TUMOR INFILTRATION AND ANTITUMOR ACTIVITY OF CART T CELLSSeptember 2021March 2025Abandon4211NoNo
17466142COMPOSITIONS FOR PREVENTING INFECTIONSeptember 2021March 2025Allow4251YesYes
17436269AMORPHOUS SOLID DISPERSION OF PYRAZOLE-AMIDE COMPOUNDSeptember 2021March 2026Abandon5421NoNo
17402172Medical Device Comprising Boswellic AcidAugust 2021May 2024Allow3311NoNo
17362203MEDICAL DEVICES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING ENHANCING COMFORT, ENHANCING DRUG PENETRATION, AND TREATMENT OF MYOPIAJune 2021September 2021Allow300YesNo
17416930PERCUTANEOUS ABSORPTION PREPARATION COMPRISING STABILIZED DONEPEZILJune 2021August 2024Allow3801NoNo
17304347BIODEGRADABLE ARTICLES AND METHODS FOR TREATMENT OF PELVIC FLOOR DISORDERS INCLUDING EXTRACELLULAR MATRIX MATERIALJune 2021November 2024Abandon4121NoNo
17342807Disintegrating Oral Tablet Suitable For Active Pharmaceutical IngredientsJune 2021July 2024Allow3721NoNo
17342960EMBOLIC COMPOSITIONS AND METHODSJune 2021September 2025Allow5121NoYes
17341785Oral Tablet For Taste Masking Of Active IngredientsJune 2021July 2024Allow3721NoNo
17317540COMPOSITIONS AND METHODS FOR TREATMENT OF BONE DEFECTSMay 2021May 2024Allow3611YesNo
17182767WATER-SOLUBLE FORMULATIONS, METHODS OF MAKING AND USEFebruary 2021September 2024Abandon4301NoNo
17180935POROUS COMPOSITE BIOMATERIALS AND RELATED METHODSFebruary 2021December 2023Abandon3411NoNo
17163113BIORESORBABLE IMPLANT WITH INSIDE-OUT RESORPTION FOR ENHANCED BONE INGROWTH AND TISSUE INTEGRATION AND METHOD OF MANUFACTURING THEREOFJanuary 2021January 2025Allow4741YesNo
17264608A BONE CEMENT COMPOSITIONJanuary 2021August 2025Abandon5421NoNo
17262987BIOMIMETIC BIOMATERIAL AND PRODUCTION METHOD THEREOFJanuary 2021September 2024Abandon4310NoNo
17108689COMPOSITIONS AND METHODS FOR ORAL ADMINISTRATION OF CANNABINOIDS AND TERPENOIDSDecember 2020March 2024Abandon3901NoNo
17059206METHOD FOR MANUFACTURING RING-SHAPED BONE GRAFTING SUBSTITUTENovember 2020March 2025Allow5222NoNo
17073312MEDICAL DEVICES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING ENHANCING COMFORT, ENHANCING DRUG PENETRATION, AND TREATMENT OF MYOPIAOctober 2020April 2021Allow601YesNo
17064475BONE REGENERATION MATERIAL HAVING A COTTON-WOOL LIKE STRUCTURE FORMED OF A PLURALITY OF ELECTROSPUN FIBERSOctober 2020August 2023Abandon3560YesNo
17032905CURABLE CALCIUM PHOSPHATE COMPOSITIONS FOR USE WITH POROUS STRUCTURES AND METHODS OF USING THE SAMESeptember 2020December 2023Abandon3921NoNo
17040999Preparation method of gradient mineralized cancellous bone matrix materialSeptember 2020February 2023Allow2900NoNo
17018491DEMINERALIZED BONE MATRIX FIBERS, METHODS OF MAKING AND USING THEMSeptember 2020April 2024Allow4321NoNo
17018708HYDRATABLE COMPOSITIONS COMPRISING MACROPARTICLES AND METHODS OF MAKING THEMSeptember 2020April 2024Allow4321NoNo
17006012ROLLABLE BONE IMPLANT FOR ENCLOSING BONE MATERIALAugust 2020December 2024Allow5261NoNo
16960778SHEETAugust 2020September 2025Abandon6040YesNo
16986524ARTICLES INCLUDING BRUSHITE FOR USE AS A BONE OR DENTAL IMPLANT AND METHODS OF FORMINGAugust 2020October 2024Abandon5021YesNo
16922422TREATED OSSEOUS PARTICULATE FLUFF COMPOSITIONJuly 2020January 2025Abandon5461YesYes

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner COUGHLIN, DANIEL F.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
23
Examiner Affirmed
16
(69.6%)
Examiner Reversed
7
(30.4%)
Reversal Percentile
47.1%
Lower than average

What This Means

With a 30.4% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
92
Allowed After Appeal Filing
26
(28.3%)
Not Allowed After Appeal Filing
66
(71.7%)
Filing Benefit Percentile
41.5%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 28.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner COUGHLIN, DANIEL F - Prosecution Strategy Guide

Executive Summary

Examiner COUGHLIN, DANIEL F works in Art Unit 1619 and has examined 530 patent applications in our dataset. With an allowance rate of 41.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 38 months.

Allowance Patterns

Examiner COUGHLIN, DANIEL F's allowance rate of 41.3% places them in the 8% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by COUGHLIN, DANIEL F receive 2.75 office actions before reaching final disposition. This places the examiner in the 80% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by COUGHLIN, DANIEL F is 38 months. This places the examiner in the 28% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +18.7% benefit to allowance rate for applications examined by COUGHLIN, DANIEL F. This interview benefit is in the 61% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 11.7% of applications are subsequently allowed. This success rate is in the 6% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 18.4% of cases where such amendments are filed. This entry rate is in the 22% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 78.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 62% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 65.7% of appeals filed. This is in the 46% percentile among all examiners. Of these withdrawals, 47.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 72.0% are granted (fully or in part). This grant rate is in the 78% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 3.6% of allowed cases (in the 82% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.